Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Uwe Thuss"'
Autor:
Stefan Klein, Isabella Gashaw, Sybille Baumann, Xinying Chang, Thomas Hummel, Uwe Thuß, Christian Friedrich
Publikováno v:
British Journal of Clinical Pharmacology. 88:4552-4564
Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080) investigated t
Autor:
Armin Schultz, Stefanie Kapsa, Stefanie Boxnick, Uwe Thuss, Sigrun Unger, Christiane Otto, Frank Schaumann
Publikováno v:
Clinical Pharmacology in Drug Development. 11:296-308
The α2C -adrenoreceptor antagonist BAY 1193397 is in development for the oral treatment of diabetic foot ulcers. Safety, tolerability, and pharmacokinetics of BAY 1193397 were investigated in 3 randomized, single-center phase 1 studies in healthy ma
Autor:
Stefanie, Kapsa, Uwe, Thuss, Stefanie, Boxnick, Frank, Schaumann, Armin, Schultz, Sigrun, Unger, Christiane, Otto
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(3)
The α
Autor:
Holger Hess-Stumpp, Marie-Pierre Collin, Stuart Ince, Oliver Politz, Uwe Thuss, Sebastian Bender, Klemens Lustig, Dieter Zopf, Christoph Kneip, Peter Ellinghaus, Dominik Mumberg, Sylvia Grünewald, Ulf Boemer, Charlotte Kopitz, Mélanie Héroult, Karl Ziegelbauer
Publikováno v:
International Journal of Cancer
Aberrant activation in fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell lung cancer, squamous cell head and neck carcinoma, colorectal and bladder cancer. Thus, fibroblast growth fa
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e111838 (2014)
Oxygen sensing by hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) is the dominant regulatory mechanism of erythropoietin (EPO) expression. In chronic kidney disease (CKD), impaired EPO expression causes anemia, which can be treated by suppleme
Externí odkaz:
https://doaj.org/article/a93a790894f74997a6827492ecbc9963
Autor:
Uwe Thuss, Dagmar Kubitza, Georg Wensing, Andreas Kaiser, E. R. Arens, Silvia Lentini, M. Böttcher, D. van der Mey
Publikováno v:
British Journal of Clinical Pharmacology. 84:1557-1565
Aims Insufficient erythropoietin (EPO) synthesis is a relevant cause of renal anaemia in patients with chronic kidney disease. Molidustat, a selective hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, increases endogenous EPO levels dos
Autor:
Mario Jeske, Gunter Karig, Jörg Keldenich, Hartmut Beck, Felix Oehme, Kai Dr. Thede, Ingo Hartung, Metin Akbaba, Hans-Christian Militzer, Jens-Kerim Ergüden, Friederike Stoll, Ingo Flamme, Uwe Thuss
Publikováno v:
ChemMedChem. 13:988-1003
Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads
Autor:
Uwe Thuss, Corinne Buisson, Mario Thevis, Cynthia Mongongu, Josef Dib, Adeline Molina, Wilhelm Schänzer
Publikováno v:
Drug Testing and Analysis. 9:61-67
The development of new therapeutics potentially exhibiting performance-enhancing properties implicates the risk of their misuse by athletes in amateur and elite sports. Such drugs necessitate preventive anti-doping research for consideration in sport
Publikováno v:
Bioanalysis. 7:2777-2787
Background: Nifurtimox is a 5-nitrofuran derived antiprotozoal drug used to treat diseases caused by trypanosomes including Chagas’ disease and sleeping sickness (African trypanosomiasis). Available methods for the determination of nifurtimox in pl
Autor:
Armin Schultz, Stefanie Boxnick, Uwe Thuß, Matthias Berse, Christiane Otto, Michael Becka, Friederike Kanefendt
Publikováno v:
Clinical pharmacology in drug development. 8(4)
The orally available chymase inhibitor BAY 1142524 is currently being developed as a first-in-class treatment for left-ventricular dysfunction after myocardial infarction. Results from 3 randomized, single-center, phase 1 studies in healthy male volu